Walter Berger at Center for Cancer Research and Comprehensive Cancer Center Medical University Vienna Borschkegasse - Research Interests, Publications & Academic Profile

Walter Berger

University Name

Austria

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacology

50%

Cell Biology

40%

Bioactive Compound

30%

Drug Formulation

30%

Tissue Imaging

20%

Metabolic Biology

20%

Immunohistochemistry

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles11

Primary and hTERT-Transduced Mesothelioma-Associated Fibroblasts but Not Primary or hTERT-Transduced Mesothelial Cells Stimulate Growth of Human Mesothelioma Cells

Article Link

Year:

2023

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs

Article Link

Year:

2023

Cannabimimetic <i>N</i>-Stearoylethanolamine as “Double-Edged Sword” in Anticancer Chemotherapy: Proapoptotic Effect on Tumor Cells and Suppression of Tumor Growth versus Its Bio-Protective Actions in Complex with Polymeric Carrier on General Toxicity of Doxorubicin In Vivo

Article Link

Year:

2023

Combination of Drug Delivery Properties of PAMAM Dendrimers and Cytotoxicity of Platinum(IV) Complexes—A More Selective Anticancer Treatment?

Article Link

Year:

2023

Multiparametric Tissue Characterization Utilizing the Cellular Metallome and Immuno-Mass Spectrometry Imaging

Article Link

Year:

2023

The Lipid Metabolism as Target and Modulator of BOLD‐100 Anticancer Activity: Crosstalk with Histone Acetylation

Article Link

Year:

2023

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance

Article Link

Year:

2022

Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance

Article Link

Year:

2022

The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation

Article Link

Year:

2022

Trabectedin Is Active against Two Novel, Patient-Derived Solitary Fibrous Pleural Tumor Cell Lines and Synergizes with Ponatinib

Article Link

Year:

2022

Cisplatin Uptake in Macrophage Subtypes at the Single-Cell Level by LA-ICP-TOFMS Imaging

Article Link

Year:

2021

Collaborators16

Michael Jakupec

Universität Wien

AUSTRIA

Éva A. Enyedy

University of Szeged

HUNGARY

Christopher Gerner

Full Professor

AUSTRIA

Christian Kowol

Associate Professor

Universität Wien

AUSTRIA

Gunda Koellensperger

Professor

AUSTRIA

Leonhard Müllauer

Pathologist/Molecular Pathologist/Associate Professor

Medical University of Vienna

AUSTRIA

Bahil Ghanim

Karl Landsteiner University of Health Sciences

AUSTRIA

Bernhard K. Keppler

AUSTRIA

Petra Heffeter

Full professor

Medical University of Vienna

AUSTRIA

Astrid Slany

Universität Wien

AUSTRIA

Evelyn Rampler

Assistant Professor

Universität Wien

AUSTRIA

Liliia Legka

Nencki Institute of Experimental Biology

POLAND

Vira Chumak

POLAND

Balazs Dome

Medical University of Vienna

AUSTRIA

Samuel M. Meier‐Menches

AUSTRIA

Michael Grusch

Assoc. Prof.

Medical University of Vienna

AUSTRIA

How do I reach out?

Meet Kite AI